BIND Biosciences Appoints Industry Veteran Daniel Lynch as Chairman of the Board of Directors

BIND Biosciences Appoints Industry Veteran Daniel Lynch as Chairman of the Board of Directors

September 20, 2012

CAMBRIDGE, Mass., Sep 20, 2012 (BUSINESS WIRE) -- BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins(TM), today announced the appointment of Daniel S. Lynch as Chairman of the company's board of directors.

Joule Partners with Audi to Accelerate Development and Commercialization of Sustainable, Carbon-Neutral Fuels

Joule Partners with Audi to Accelerate Development and Commercialization of Sustainable, Carbon-Neutral Fuels

September 17, 2012

BEDFORD, Mass.--(BUSINESS WIRE)--

Tangent Medical Receives FDA Clearance for the NovaCath™ Secure IV Catheter System

Tangent Medical Receives FDA Clearance for the NovaCath™ Secure IV Catheter System

September 13, 2012

ANN ARBOR, Mich., Sept. 13, 2012 /PRNewswire/ -- Tangent Medical (www.tangentmedical.com), an innovator in IV therapy products, today announced it has received FDA 510(k) clearance for the NovaCath™ Secure IV Catheter System, a product designed to set new standards in peripheral IV catheter design, functionality and performance.

LS9 Announces Successful Start-up of Florida Demonstration Facility

LS9 Announces Successful Start-up of Florida Demonstration Facility

September 10, 2012

First Production Run Achieves Technical Goals

Joule Commissions First SunSprings™ Plant to Demonstrate Commercial Readiness

Joule Commissions First SunSprings™ Plant to Demonstrate Commercial Readiness

September 11, 2012

BEDFORD, Mass.--(BUSINESS WIRE)--

Visterra Appoints Donna M. Ambrosino as Chief Medical Officer

Visterra Appoints Donna M. Ambrosino as Chief Medical Officer

September 11, 2012

CAMBRIDGE, Mass., Sep 11, 2012 (BUSINESS WIRE) -- Visterra, Inc., developer of novel therapeutics to treat major diseases, announced today that it has appointed Donna M. Ambrosino, M.D., as chief medical officer. Dr. Ambrosino will oversee all drug development activities for the company, including the company's lead drug candidate against influenza, VIS410, and she will serve as a member of the company's executive management team.

Visterra Signs Antibody Discovery Collaboration Deal With Pfizer

Visterra Signs Antibody Discovery Collaboration Deal With Pfizer

September 11, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra’s proprietary platform.   

Visterra Presents Preclinical Results that Shows 100% Prevention and Treatment of Influenza with VIS410, a Novel Engineered Human Antibody

Visterra Presents Preclinical Results that Shows 100% Prevention and Treatment of Influenza with VIS410, a Novel Engineered Human Antibody

September 10, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., developer of novel therapeutics to treat major diseases, today announced the presentation of positive data from a preclinical study evaluating the efficacy of the company’s lead product candidate, VIS410, a broadly protective, fully human monoclonal antibody being developed for influenza A infections.

Joule Elects Caroline Dorsa to Board of Directors

Joule Elects Caroline Dorsa to Board of Directors

September 4, 2012

Bedford, MA – September 4, 2012 – Joule today announced the election of Caroline Dorsa to its board of directors, adding the expertise and insight of a highly experienced financial executive who will also serve as Chair of the company's audit committee.

Startup WikiCell Designs Secures $10 Million in Investment Capital from Flagship Ventures and Polaris Venture Partners

Startup WikiCell Designs Secures $10 Million in Investment Capital from Flagship Ventures and Polaris Venture Partners

September 4, 2012

Company Anticipates Introduction of First Edible Packaged Products in 2013